Security key
31572Q808
KYNTRA BIO, INC. - Common Stock, $0.01 par value (FGEN)
CUSIP: 31572Q808
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.01 par value
- Total 13F shares
- 15,000
- Total 13F value
- $79,500
- Share change
- -32,958,387
- SEC-reported price per share
- $5.30
- Number of holders
- 1
- Value change
- -$10,137,427
- Number of buys
- 1
- Number of sells
- 51
- Shares outstanding
- 4,048,583
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
1
Top holders
1
FGEN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
KYNTRA BIO, INC. SEC filings
KYNTRA BIO, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 31572Q808
Recent filing periods:
Ownership snapshot
Top reported holders of FGEN - KYNTRA BIO, INC. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
13D/G
Lead comparable stake: 8.3%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 8.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
8.3%
PRIMECAP MANAGEMENT CO/CA/
4.6%
VANGUARD GROUP INC
4.4%
ACADIAN ASSET MANAGEMENT LLC
96%
MARSHALL WACE, LLP
55%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$2,634,150
8,500,000 shares
|
— | 31 Mar 2025 |
| PRIMECAP MANAGEMENT CO/CA/ |
13D/G
13F
Company
|
4.6%
|
$1,523,323
4,616,130 shares
|
$0 | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
13D/G
Company · The Vanguard Group
|
4.4%
from 13D/G
|
$1,816,329
5,859,125 shares
|
— | 31 Mar 2025 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
96%
|
$1,208,000
3,905,350 shares
|
— | 31 Mar 2025 |
| MARSHALL WACE, LLP |
13F
Company
|
55%
|
$685,893
2,212,561 shares
|
— | 31 Mar 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
27%
|
$334,625
1,079,496 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
15,000
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
52
Q2 2025 holders
1
Holder diff
-51
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend